Skip to main content
SpringerLink
Log in

Activity of ceftolozane/tazobactam and imipenem/relebactam against clinical gram-negative isolates from Czech Republic, Hungary, and Poland—SMART 2017–2020

  • Brief Report
  • Published:
European Journal of Clinical Microbiology & Infectious Diseases Aims and scope Submit manuscript

Abstract

Antimicrobial susceptibility was determined for clinical gram-negative isolates from Czech Republic, Hungary, and Poland, where published data for ceftolozane/tazobactam (C/T) and imipenem/relebactam (IMI/REL) is scarce. C/T was active against 94.3% of Enterobacterales, 10–18% higher than the tested cephalosporins and piperacillin/tazobactam. IMI/REL was the most active tested agent against non-Morganellaceae Enterobacterales (99.7% susceptible). C/T was the most active among all studied agents except colistin against Pseudomonas aeruginosa (96.0% susceptible); susceptibility to IMI/REL was 90.7%. C/T maintained activity against 73.7–85.3% of β-lactam-resistant or multidrug-resistant P. aeruginosa subsets. C/T and IMI/REL could represent important treatment options for patients from these countries.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Data availability

Data available on reasonable request.

References

  1. World Health Organization (2017) WHO publishes list of bacteria for which new antibiotics are urgently needed.https://www.who.int/news/item/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed

  2. Clinical and Laboratory Standards Institute (2018) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 11th ed, M07-A11. Approved standard. Clinical and Laboratory Standards Institute, Wayne, PA

  3. European Committee on Antimicrobial Susceptibility Testing (2021) Breakpoint tables for interpretation of MICs and zone diameters. Version 11.0. https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_11.0_Breakpoint_Tables.pdf

  4. Clinical and Laboratory Standards Institute (2021) M100 performance standards for antimicrobial susceptibility testing, 31st ed. Clinical and Laboratory Standards Institute, Wayne, PA

  5. Lob SH, Biedenbach DJ, Badal RE, Kazmierczak KM, Sahm DF (2015) Antimicrobial resistance and resistance mechanisms of Enterobacteriaceae in ICU and non-ICU wards in Europe and North America: SMART 2011–2013. J Glob Antimicrob Resist 3:190–197

    Article  CAS  Google Scholar 

  6. Nichols WW, de Jonge BL, Kazmierczak KM, Karlowsky JA, Sahm DF (2016) In vitro susceptibility of global surveillance isolates of Pseudomonas aeruginosa to ceftazidime-avibactam (INFORM 2012 to 2014). Antimicrob Agents Chemother 60:4743–4749

    Article  CAS  Google Scholar 

  7. Estabrook M, Kazmierczak KM, Wise M, Arhin FF, Stone GG, Sahm DF (2021) Molecular characterization of clinical isolates of Enterobacterales with elevated MIC values for aztreonam-avibactam from the INFORM global surveillance study, 2012–2017. J Glob Antimicrob Resist 24:316–320

    Article  CAS  Google Scholar 

  8. Bortolaia V, Kaas RS, Ruppe E, Roberts MC, Schwarz S, Cattoir V et al (2020) ResFinder 4.0 for predictions of phenotypes from genotypes. J Antimicrob Chemother 75:3491–500

    Article  CAS  Google Scholar 

  9. Adámková V, Mareković I, Szabó J, Pojnar L, Billová S, Horvat Herceg S et al (2022) Antimicrobial activity of ceftazidime-avibactam and comparators against Pseudomonas aeruginosa and Enterobacterales collected in Croatia, Czech Republic, Hungary, Poland, Latvia and Lithuania: ATLAS Surveillance Program, 2019. Eur J. Clin Microbiol Infect Dis : Off Publ Eur Soc Clin Microbiol 41:989–996

    Article  Google Scholar 

  10. Zalas-Więcek P, Prażyńska M, Pojnar Ł, Pałka A, Żabicka D, Orczykowska-Kotyna M et al (2022) Ceftazidime/avibactam and other commonly used antibiotics activity against Enterobacterales and Pseudomonas aeruginosa isolated in Poland in 2015–2019. Infect Drug Resist 15:1289–1304

    Article  Google Scholar 

Download references

Acknowledgements

The authors thank all SMART participants for their contributions to the program.

Funding

Funding for this research, which included compensation for services related to preparing this manuscript, was provided by Merck Sharp and Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

Author information

Authors and Affiliations

  1. IHMA, Schaumburg, IL, USA

    Sibylle H. Lob & Daniel F. Sahm

  2. IHMA, Monthey, Switzerland

    Stephen P. Hawser

  3. Merck & Co., Inc., NJ, Rahway, USA

    Fakhar Siddiqui, C. Andrew DeRyke, Katherine Young & Mary R. Motyl

  4. MSD, Dubai, United Arab Emirates

    Irina Alekseeva

Authors
  1. Sibylle H. Lob
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stephen P. Hawser
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Fakhar Siddiqui
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Irina Alekseeva
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. C. Andrew DeRyke
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Katherine Young
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Mary R. Motyl
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Daniel F. Sahm
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Sibylle Lob: conceptualization, methodology, analysis, writing—original draft; Stephen Hawser: investigation, writing—review and editing; Katherine Young: conceptualization, methodology, writing—review and editing; Mary Motyl: conceptualization, methodology, writing—review and editing; Daniel Sahm: conceptualization, methodology, writing—review and editing, supervision. All authors have read and approved the final manuscript.

Corresponding author

Correspondence to Sibylle H. Lob.

Ethics declarations

Ethics approval

Not required.

Competing interests

SHL, SPH, and DFS work for IHMA, which receives funding from Merck Sharp and Dohme LLC, a subsidiary of Merck and Co., Inc., Rahway, NJ, USA, for the SMART global surveillance program. FS, IA, CAD, KY, and MRM are employees of Merck Sharp and Dohme LLC, a subsidiary of Merck and Co., Inc., Rahway, NJ, USA, and own stock in Merck and Co., Inc., Rahway, NJ, USA. The IHMA authors do not have personal financial interests in the sponsor of this paper (Merck Sharp and Dohme LLC, a subsidiary of Merck and Co., Inc., Rahway, NJ, USA).

Additional information

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lob, S.H., Hawser, S.P., Siddiqui, F. et al. Activity of ceftolozane/tazobactam and imipenem/relebactam against clinical gram-negative isolates from Czech Republic, Hungary, and Poland—SMART 2017–2020. Eur J Clin Microbiol Infect Dis 42, 365–370 (2023). https://doi.org/10.1007/s10096-023-04549-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10096-023-04549-1

Keywords

Search

Navigation